IDH assay facilitates timelier leukemia treatment: Rong He, M.D.
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
About this episode
Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test speeds therapeutic decision making for adults with acute myeloid leukemia, or AML. The standalone assay yields faster results than next generation sequencing.
(00:32)
Would you provide a brief background of yourself?
(01:42)
Could you give an overview of the IDHQ test?
(02:25)
Is there anything more you'd like to touch on about the droplet digital PCR approach and high sensitivity?
(03:09)
Why are IDH1 and IDH2 important in disease diagnosis, prognosis, or therapeutic management?
(05:00)
Is there anything else you'd like to say about this particular assay?
(06:56)
Would you describe the specific group of patients where testing is recommended?
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Answers from the Lab
Unique Assays Advance Care of Complex Autoimmune Skin Conditions
Answers from the Lab
Digital Advances: What’s Next for Clinical Diagnostics?
Answers from the Lab
Preeclampsia Test Helps Extend Pregnancy to Improve Outcomes
Answers from the Lab
Breakthrough Test Enhances Peripheral Neuropathy Care and Research
Answers from the Lab